1. Home
  2. OLED vs DNLI Comparison

OLED vs DNLI Comparison

Compare OLED & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Display Corporation

OLED

Universal Display Corporation

SELL

Current Price

$75.38

Market Cap

3.4B

Sector

Technology

ML Signal

SELL

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

SELL

Current Price

$18.44

Market Cap

3.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OLED
DNLI
Founded
1985
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.4B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
OLED
DNLI
Price
$75.38
$18.44
Analyst Decision
Buy
Strong Buy
Analyst Count
9
20
Target Price
★ $113.82
$35.75
AVG Volume (30 Days)
699.8K
★ 1.7M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
★ 2.66%
N/A
EPS Growth
★ 9.25
N/A
EPS
★ 1.82
N/A
Revenue
★ $650,611,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.56
$156.11
P/E Ratio
$41.26
★ N/A
Revenue Growth
★ 0.45
N/A
52 Week Low
$70.77
$13.75
52 Week High
$153.38
$27.30

Technical Indicators

Market Signals
Indicator
OLED
DNLI
Relative Strength Index (RSI) 44.16 30.82
Support Level $73.23 $18.07
Resistance Level $81.15 $20.84
Average True Range (ATR) 2.54 0.73
MACD 0.01 -0.06
Stochastic Oscillator 47.86 8.68

Price Performance

Historical Comparison
OLED
DNLI

About OLED Universal Display Corporation

Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: